Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China · Delayed Price · Currency is CNY

58.01

+2.19 (3.92%)

Sep 30, 2026, 4:00 PM EDT

Market Cap	26.98B -17.3%
Revenue (ttm)	968.83M +89.5%
Net Income	-597.06M
EPS	-1.29
Shares Out	465.17M
PE Ratio	n/a
Forward PE	21.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,285,178
Open	57.30
Previous Close	55.82
Day's Range	55.57 - 60.00
52-Week Range	35.73 - 73.50
Beta	-0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., L... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2017

Employees 990

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688192

Full Company Profile

Financial Performance

In 2025, SHA:688192's revenue was 801.14 million, an increase of 122.60% compared to the previous year's 359.90 million. Losses were -764.05 million, -9.68% less than in 2024.

Financial Statements